Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
Keywords: ABO blood group system; Adverse drug event; Renal cell carcinoma; Treatment outcome; Survival; Targeted molecular therapy;